Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 13
1963 5
1964 6
1965 3
1966 5
1967 3
1968 4
1969 5
1970 8
1971 4
1972 3
1973 4
1974 10
1975 6
1976 3
1977 7
1978 19
1979 18
1980 20
1981 19
1982 14
1983 17
1984 32
1985 19
1986 22
1987 18
1988 21
1989 26
1990 28
1991 27
1992 22
1993 24
1994 28
1995 23
1996 27
1997 13
1998 20
1999 35
2000 20
2001 30
2002 28
2003 25
2004 23
2005 31
2006 29
2007 27
2008 28
2009 21
2010 31
2011 41
2012 53
2013 82
2014 77
2015 87
2016 96
2017 113
2018 100
2019 99
2020 121
2021 134
2022 104
2023 92
2024 83
2025 27

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,048 results

Results by year

Filters applied: . Clear all
Page 1
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone group. Indacaterol-glycopyrronium showed not only noninferiority but also superiority to salmeterol-fluticasone in reducing the annual rat …
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone group …
Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Heo YA. Heo YA. Drugs. 2021 Aug;81(12):1411-1422. doi: 10.1007/s40265-021-01562-6. Epub 2021 Aug 3. Drugs. 2021. PMID: 34342835 Free PMC article. Review.
In two pivotal phase III trials of 24-52 weeks' duration, budesonide/glycopyrronium/formoterol reduced the rates of moderate/severe COPD exacerbations and improved lung function to a greater extent than budesonide/formoterol and/or glycopyrronium/formoterol. ...Bude …
In two pivotal phase III trials of 24-52 weeks' duration, budesonide/glycopyrronium/formoterol reduced the rates of moderate/severe C …
Glycopyrronium/Formoterol: A Review in COPD.
Al-Salama ZT, Frampton JE. Al-Salama ZT, et al. Drugs. 2019 Sep;79(13):1455-1466. doi: 10.1007/s40265-019-01186-x. Drugs. 2019. PMID: 31468315 Review.
Glycopyrronium/formoterol (Bevespi Aerosphere()) is a fixed-dose combination of the long-acting muscarinic antagonist glycopyrronium bromide and the long-acting beta(2)-agonist formoterol fumarate delivered via a pressurized metered dose inhaler (pMDI) and formulate …
Glycopyrronium/formoterol (Bevespi Aerosphere()) is a fixed-dose combination of the long-acting muscarinic antagonist glycopyrroni …
Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis.
Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, Tyring SK. Nwannunu CE, et al. Skin Therapy Lett. 2019 Mar;24(2):1-3. Skin Therapy Lett. 2019. PMID: 30970203 Free article. Review.
In clinical trials, topical glycopyrronium tosylate, a pre-moistened cloth containing 2.4% glycopyrronium solution, was shown to be an effective, safe and non-invasive treatment for patients suffering from primary hyperhidrosis. This review examines the clinical tri …
In clinical trials, topical glycopyrronium tosylate, a pre-moistened cloth containing 2.4% glycopyrronium solution, was shown …
Glycopyrrolate.
Mirakhur RK, Dundee JW. Mirakhur RK, et al. Gen Pharmacol. 1981;12(6):423-7. doi: 10.1016/0306-3623(81)90064-1. Gen Pharmacol. 1981. PMID: 7030865 Review. No abstract available.
Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Banerji D, Fogel R, Patalano F. Banerji D, et al. Drug Discov Today. 2018 Jan;23(1):196-203. doi: 10.1016/j.drudis.2017.10.015. Epub 2017 Oct 24. Drug Discov Today. 2018. PMID: 29079130 Review.
Indacaterol/glycopyrronium (IND/GLY) 110/50mcg was the first once-daily, long-acting beta(2)-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC) approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD). ...
Indacaterol/glycopyrronium (IND/GLY) 110/50mcg was the first once-daily, long-acting beta(2)-agonist (LABA)/long-acting muscarinic an …
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Chapman KR, Hurst JR, Frent SM, Larbig M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA. Chapman KR, et al. Am J Respir Crit Care Med. 2018 Aug 1;198(3):329-339. doi: 10.1164/rccm.201803-0405OC. Am J Respir Crit Care Med. 2018. PMID: 29779416 Free article. Clinical Trial.
OBJECTIVES: To evaluate the efficacy and safety of direct de-escalation from long-term triple therapy to indacaterol/glycopyrronium in nonfrequently exacerbating patients with chronic obstructive pulmonary disease (COPD). ...CONCLUSIONS: In patients with COPD without frequ …
OBJECTIVES: To evaluate the efficacy and safety of direct de-escalation from long-term triple therapy to indacaterol/glycopyrronium i …
Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
Blair HA. Blair HA. Drugs. 2021 Apr;81(6):709-719. doi: 10.1007/s40265-021-01518-w. Epub 2021 Apr 19. Drugs. 2021. PMID: 33871819 Review.
Indacaterol/glycopyrronium/mometasone was generally well tolerated, and the most common adverse events were respiratory in nature. ...Indacaterol/glycopyrronium/mometasone was generally well tolerated. The most common adverse events were respiratory-related. ...
Indacaterol/glycopyrronium/mometasone was generally well tolerated, and the most common adverse events were respiratory in nature. .. …
TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life.
Richeldi L, Schino P, Bargagli E, Ricci A, Rocca A, Marchesani F, Pennisi A, Camiciottoli G, D'Amato M, Macagno F, Scaffidi Argentina U, Ingrassia E, Piraino A. Richeldi L, et al. Int J Chron Obstruct Pulmon Dis. 2024 Feb 23;19:475-487. doi: 10.2147/COPD.S445858. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 38435125 Free PMC article.
PURPOSE: The TRITRIAL study assessed the effects of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) fixed combination in patients with chronic obstructive pulmonary disease (COPD) in a real-world setting, focusing on patient's experience and perspe …
PURPOSE: The TRITRIAL study assessed the effects of beclometasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) fixed co …
2,048 results